DOCUMENT
1/1
Talking about risk in the context of genomic tests (TARGET): development and evaluation of an educational programme for clinicians
journal contribution
posted on 2023-06-12, 09:08 authored by Lesley FallowfieldLesley Fallowfield, I Solis-Trapala, Rachel StarkingsRachel Starkings, Susan Catt, Shirley MayShirley May, Valerie JenkinsValerie JenkinsPurpose: Gene expression profiling (GEP) test scores calculate risks of recurrence and likely benefit of adjuvant chemotherapy in ER positive, HER2 negative, early stage breast cancer. As health literacy and numeracy skills in the general population are poor, healthcare professionals (HCPs) require a wide repertoire of communication skills to explain clearly risk of recurrence scores (RSs) and uncertainty. We developed and evaluated an educational program for HCPs discussing GEP test results and adjuvant treatment. Methods: Eight hour workshops contained elements aimed at improving knowledge, communication skills, and self-awareness; these included:- the science underpinning GEP tests, an interactive risk psychology lecture, exercises and facilitated group discussions regarding 7 filmed scenarios involving discussions about high, intermediate and low RSs. Attendees were recorded explaining RSs with patient simulators pre and post workshop. Researchers blinded to time-point, analysed recordings using a study specific scoring system. Primary objective outcomes were improvements post workshop in HCPs’ competence and confidence when communicating 17 pre-specified key information areas. We estimated odds ratios (OR) using conditional logistic regression to compare pre and post workshop scores. Results: 65 HCPs attended. Objective analyses revealed significant positive shifts post-workshop which included explaining:- GEP tests (OR=2.98; 95% CI, 1.38 to 6.42; P=.001), recurrence RSs (OR=3.99; 95% CI, 1.72 to 9.25; P<.001), benefits of chemotherapy (OR= 3.99; 95% CI, 1.82 to 8.75; P<.001; and harms OR=2.31; 95% CI, 1.37 to 3.92; P<.001) using jargon free language (OR=5.29; 95% CI, 2.27 to 12.35; P<.001). Patient simulator assessments also showed significant improvements as did HCPs’ self-assessments and ratings of their self-confidence when discussing different GEP tests with diverse patient types (P<.001). Conclusion: These short, intensive, interactive TARGET workshops significantly improved HCPs’ communication about GEP results in ways likely to promote more informed decision-making by patients about chemotherapy.
Funding
Talking About Risk in the context of GEnomic profiling Tests (TARGET); BREAST CANCER RESEARCH FOUNDATION; BCRF-17-050
History
Publication status
- Published
File Version
- Published version
Journal
Breast Cancer Research and TreatmentISSN
0167-6806Publisher
SpringerExternal DOI
Department affiliated with
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications
Research groups affiliated with
- Sussex Health Outcomes Research and Education in Cancer Publications
Full text available
- Yes
Peer reviewed?
- Yes